Symbols / RLMD Stock $6.31 -0.32% Relmada Therapeutics, Inc.
RLMD (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteRelmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Ratings
Current target
$6.31
Low
$9.00
High
$19.00
Mean
$12.80
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-24 | init | Piper Sandler | — → Overweight | $12 |
| 2026-03-20 | main | Mizuho | Outperform → Outperform | $19 |
| 2026-03-02 | init | LUCID CAPITAL MARKETS | — → Buy | $14 |
| 2026-01-23 | up | Leerink Partners | Market Perform → Outperform | $8 |
| 2025-12-22 | init | Jefferies | — → Buy | $9 |
| 2025-11-19 | up | Mizuho | Neutral → Outperform | $10 |
| 2024-12-05 | down | Mizuho | Outperform → Neutral | $1 |
| 2024-12-04 | down | Leerink Partners | Outperform → Market Perform | $1 |
| 2024-06-05 | down | Goldman Sachs | Neutral → Sell | $2 |
| 2023-06-15 | reit | Mizuho | Buy → Buy | $26 |
| 2023-01-23 | main | SVB Leerink | — → Outperform | $10 |
| 2022-10-14 | down | Goldman Sachs | Buy → Neutral | $8 |
| 2022-10-14 | down | Guggenheim | Buy → Neutral | — |
| 2022-10-13 | down | Oppenheimer | Outperform → Perform | — |
| 2022-09-23 | main | Goldman Sachs | — → Buy | $81 |
| 2022-09-06 | main | Guggenheim | — → Buy | $60 |
| 2022-05-09 | main | Oppenheimer | — → Outperform | $64 |
| 2022-03-24 | main | Goldman Sachs | — → Buy | $53 |
| 2021-12-20 | main | SVB Leerink | — → Outperform | $42 |
| 2021-11-18 | init | Mizuho | — → Buy | $50 |
- RLMD Stock Chart | RELMADA THERAPEUTICS INC (NASDAQ:RLMD) - ChartMill Mon, 01 Jun 2026 07
- Biotech Relmada CEO, CFO in Jefferies fireside chat June 4 - Stock Titan hu, 28 May 2026 11
- Here’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock - Yahoo Finance ue, 24 Mar 2026 07
- Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Mov - Benzinga Wed, 03 Jun 2026 12
- RELMADA THERAPEUTICS ($RLMD) Releases Q1 2026 Earnings - Quiver Quantitative ue, 12 May 2026 07
- RLMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI Wed, 03 Jun 2026 13
- RLMD Stock Surges 42% in a Week: Here's What You Should Know - TradingView hu, 12 Mar 2026 07
- Relmada wins bullish view at Piper Sandler on cancer therapy - Seeking Alpha ue, 24 Mar 2026 07
- Dow, S&P 500, Nasdaq futures dip after Wall Street rebound: Why SLS, ZVRA, RLMD, USO, CASY are trending after-hours - MSN Sun, 26 Apr 2026 08
- Why Is RLMD Stock Surging Premarket? NDV-01 Trial Update and $160M PIPE Deal - Tokenist Mon, 09 Mar 2026 07
- Bladder cancer drug shows 95% response as Relmada readies Phase 3 - Stock Titan ue, 12 May 2026 07
- Relmada Therapeutics jumps on NDV-01 12-month Phase 2 data and $160M private placement - Quiver Quantitative Mon, 09 Mar 2026 07
- Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect? - Yahoo Finance Mon, 13 Apr 2026 07
- Biotech Relmada will discuss Q1 results and business update May 12 - Stock Titan Wed, 06 May 2026 07
- Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data - Yahoo Finance ue, 23 Sep 2025 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
59.10
-29.55%
|
83.89
-19.10%
|
103.70
-35.69%
|
161.25
|
| Research And Development |
|
26.88
-41.79%
|
46.18
-15.75%
|
54.81
-51.64%
|
113.32
|
| Selling General And Administration |
|
32.22
-14.57%
|
37.72
-22.86%
|
48.89
+2.02%
|
47.93
|
| General And Administrative Expense |
|
32.22
-14.57%
|
37.72
-22.86%
|
48.89
+2.02%
|
47.93
|
| Other Gand A |
|
32.22
-14.57%
|
37.72
-22.86%
|
48.89
+2.02%
|
47.93
|
| Total Expenses |
|
59.10
-29.55%
|
83.89
-19.10%
|
103.70
-35.69%
|
161.25
|
| Operating Income |
|
-59.10
+29.55%
|
-83.89
+19.10%
|
-103.70
+35.69%
|
-161.25
|
| Total Operating Income As Reported |
|
-59.10
+29.55%
|
-83.89
+19.10%
|
-103.70
+35.69%
|
-161.25
|
| EBITDA |
|
-59.10
+29.55%
|
-83.89
+19.10%
|
-103.70
+35.69%
|
-161.25
|
| Normalized EBITDA |
|
-59.42
+29.49%
|
-84.27
+18.55%
|
-103.46
+33.87%
|
-156.44
|
| Reconciled Depreciation |
|
—
|
—
|
—
|
0.00
|
| EBIT |
|
-59.10
+29.55%
|
-83.89
+19.10%
|
-103.70
+35.69%
|
-161.25
|
| Total Unusual Items |
|
0.32
-16.41%
|
0.38
+258.26%
|
-0.24
+94.98%
|
-4.81
|
| Total Unusual Items Excluding Goodwill |
|
0.32
-16.41%
|
0.38
+258.26%
|
-0.24
+94.98%
|
-4.81
|
| Net Income |
|
-57.39
+28.25%
|
-79.98
+19.04%
|
-98.79
+37.09%
|
-157.04
|
| Pretax Income |
|
-57.39
+28.25%
|
-79.98
+19.04%
|
-98.79
+37.09%
|
-157.04
|
| Net Non Operating Interest Income Expense |
|
1.40
-60.45%
|
3.53
-31.48%
|
5.15
+93.72%
|
2.66
|
| Net Interest Income |
|
1.40
-60.45%
|
3.53
-31.48%
|
5.15
+93.72%
|
2.66
|
| Interest Income Non Operating |
|
1.40
-60.45%
|
3.53
-31.48%
|
5.15
+93.72%
|
2.66
|
| Interest Income |
|
1.40
-60.45%
|
3.53
-31.48%
|
5.15
+93.72%
|
2.66
|
| Other Income Expense |
|
0.32
-16.41%
|
0.38
+258.26%
|
-0.24
-115.60%
|
1.55
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
6.35
|
| Gain On Sale Of Security |
|
0.32
-16.41%
|
0.38
+258.26%
|
-0.24
+94.98%
|
-4.81
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-57.39
+28.25%
|
-79.98
+19.04%
|
-98.79
+37.09%
|
-157.04
|
| Net Income From Continuing Operation Net Minority Interest |
|
-57.39
+28.25%
|
-79.98
+19.04%
|
-98.79
+37.09%
|
-157.04
|
| Net Income From Continuing And Discontinued Operation |
|
-57.39
+28.25%
|
-79.98
+19.04%
|
-98.79
+37.09%
|
-157.04
|
| Net Income Continuous Operations |
|
-57.39
+28.25%
|
-79.98
+19.04%
|
-98.79
+37.09%
|
-157.04
|
| Normalized Income |
|
-57.70
+28.19%
|
-80.36
+18.46%
|
-98.55
+35.27%
|
-152.24
|
| Net Income Common Stockholders |
|
-57.39
+28.25%
|
-79.98
+19.04%
|
-98.79
+37.09%
|
-157.04
|
| Diluted EPS |
|
-1.45
+45.28%
|
-2.65
+19.21%
|
-3.28
+38.11%
|
-5.30
|
| Basic EPS |
|
-1.45
+45.28%
|
-2.65
+19.21%
|
-3.28
+38.11%
|
-5.30
|
| Basic Average Shares |
|
39.48
+30.88%
|
30.16
+0.21%
|
30.10
+1.59%
|
29.63
|
| Diluted Average Shares |
|
39.48
+30.88%
|
30.16
+0.21%
|
30.10
+1.59%
|
29.63
|
| Diluted NI Availto Com Stockholders |
|
-57.39
+28.25%
|
-79.98
+19.04%
|
-98.79
+37.09%
|
-157.04
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
97.55
|
| Current Assets |
|
97.51
|
| Cash Cash Equivalents And Short Term Investments |
|
96.32
|
| Cash And Cash Equivalents |
|
4.09
|
| Cash Financial |
|
—
|
| Other Short Term Investments |
|
92.23
|
| Receivables |
|
0.00
|
| Other Receivables |
|
—
|
| Prepaid Assets |
|
1.19
|
| Other Current Assets |
|
—
|
| Total Non Current Assets |
|
0.04
|
| Net PPE |
|
—
|
| Gross PPE |
|
—
|
| Accumulated Depreciation |
|
—
|
| Machinery Furniture Equipment |
|
—
|
| Other Non Current Assets |
|
0.04
|
| Total Liabilities Net Minority Interest |
|
12.19
|
| Current Liabilities |
|
12.19
|
| Payables And Accrued Expenses |
|
9.19
|
| Payables |
|
3.51
|
| Accounts Payable |
|
3.51
|
| Current Accrued Expenses |
|
5.68
|
| Employee Benefits |
|
0.00
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.00
|
| Other Current Liabilities |
|
-0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
| Stockholders Equity |
|
85.36
|
| Common Stock Equity |
|
85.36
|
| Capital Stock |
|
0.03
|
| Common Stock |
|
0.03
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
30.10
|
| Ordinary Shares Number |
|
30.10
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
646.23
|
| Retained Earnings |
|
-560.90
|
| Total Equity Gross Minority Interest |
|
85.36
|
| Total Capitalization |
|
85.36
|
| Working Capital |
|
85.31
|
| Invested Capital |
|
85.36
|
| Net Tangible Assets |
|
85.36
|
| Tangible Book Value |
|
85.36
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-45.79
+11.53%
|
-51.76
-0.19%
|
-51.66
+50.23%
|
-103.80
|
| Cash Flow From Continuing Operating Activities |
|
-45.79
+11.53%
|
-51.76
-0.19%
|
-51.66
+50.23%
|
-103.80
|
| Net Income From Continuing Operations |
|
-57.39
+28.25%
|
-79.98
+19.04%
|
-98.79
+37.09%
|
-157.04
|
| Depreciation Amortization Depletion |
|
—
|
—
|
—
|
0.00
|
| Depreciation |
|
—
|
—
|
—
|
0.00
|
| Depreciation And Amortization |
|
—
|
—
|
—
|
0.00
|
| Other Non Cash Items |
|
0.91
|
—
|
—
|
-6.35
|
| Stock Based Compensation |
|
14.96
-50.44%
|
30.19
-31.09%
|
43.81
-0.87%
|
44.19
|
| Operating Gains Losses |
|
0.08
+121.13%
|
-0.37
-109.22%
|
4.06
+594.15%
|
0.59
|
| Gain Loss On Investment Securities |
|
0.08
+121.13%
|
-0.37
-109.22%
|
4.06
+594.15%
|
0.59
|
| Unrealized Gain Loss On Investment Securities |
|
-0.40
-5813.21%
|
-0.01
+99.82%
|
-3.82
-190.59%
|
4.22
|
| Change In Working Capital |
|
-3.95
-149.40%
|
-1.58
-151.41%
|
3.08
-70.92%
|
10.59
|
| Change In Receivables |
|
—
|
0.00
-100.00%
|
0.51
+220.27%
|
-0.43
|
| Change In Prepaid Assets |
|
-0.09
-127.77%
|
0.32
-88.75%
|
2.84
-60.85%
|
7.26
|
| Change In Payables And Accrued Expense |
|
-3.86
-102.84%
|
-1.90
-594.48%
|
-0.27
-107.29%
|
3.76
|
| Change In Accrued Expense |
|
-1.30
+48.61%
|
-2.53
-270.60%
|
1.48
-55.61%
|
3.34
|
| Change In Payable |
|
-2.56
-510.15%
|
0.62
+135.57%
|
-1.76
-517.05%
|
0.42
|
| Change In Account Payable |
|
-2.56
-510.15%
|
0.62
+135.57%
|
-1.76
-517.05%
|
0.42
|
| Investing Cash Flow |
|
-48.14
-193.36%
|
51.56
+2.20%
|
50.45
+155.67%
|
19.73
|
| Cash Flow From Continuing Investing Activities |
|
-48.14
-193.36%
|
51.56
+2.20%
|
50.45
+155.67%
|
19.73
|
| Net Investment Purchase And Sale |
|
-48.14
-193.36%
|
51.56
+2.20%
|
50.45
+155.67%
|
19.73
|
| Purchase Of Investment |
|
-83.83
-593.97%
|
-12.08
+86.65%
|
-90.46
-91.28%
|
-47.29
|
| Sale Of Investment |
|
35.69
-43.92%
|
63.64
-54.84%
|
140.92
+110.24%
|
67.03
|
| Financing Cash Flow |
|
93.56
+232034.78%
|
-0.04
+59.03%
|
-0.10
-100.22%
|
45.02
|
| Cash Flow From Continuing Financing Activities |
|
93.56
+232034.78%
|
-0.04
+59.03%
|
-0.10
-100.22%
|
45.02
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
93.64
|
0.00
|
0.00
-100.00%
|
42.73
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.25
|
0.00
-100.00%
|
1.97
|
| Net Other Financing Charges |
|
-0.07
+74.56%
|
-0.29
-191.57%
|
-0.10
-130.42%
|
0.32
|
| Changes In Cash |
|
-0.36
-53.70%
|
-0.23
+82.02%
|
-1.30
+96.66%
|
-39.05
|
| Beginning Cash Position |
|
3.86
-5.73%
|
4.09
-24.17%
|
5.40
-87.86%
|
44.44
|
| End Cash Position |
|
3.50
-9.35%
|
3.86
-5.73%
|
4.09
-24.17%
|
5.40
|
| Free Cash Flow |
|
-45.79
+11.53%
|
-51.76
-0.19%
|
-51.66
+50.23%
|
-103.80
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
93.64
|
0.00
|
0.00
-100.00%
|
42.73
|
| Issuance Of Capital Stock |
|
93.64
|
0.00
|
0.00
-100.00%
|
42.73
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-05-28 View
- 8-K2026-05-12 View
- 10-Q2026-05-12 View
- 8-K2026-03-20 View
- 10-K2026-03-19 View
- 8-K2026-03-09 View
- 42025-12-16 View
- 42025-12-16 View
- 42025-12-16 View
- 42025-12-16 View
- 42025-12-16 View
- 42025-12-16 View
- 42025-12-16 View
- 8-K2025-12-15 View
- 8-K2025-11-13 View
- 10-Q2025-11-13 View
- 42025-11-06 View
- 42025-11-06 View
- 42025-11-06 View
- 42025-11-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|